What genetic factors determine if GLP-1 therapy will work for me
In the debut episode of the Site Realities podcast series, our CEO, Mimi Fenton, M.P.H., Ph.D, joins Tammy D'Lugin-Monroe (Head of Sites and Patient Solutions at Syneos Health) for a candid look at the clinical landscape
Abstract Background and objective Obesity is common in heart failure (HF), worsening quality of life and depressive symptoms
The trial included a non-alcoholic fatty liver disease (NAFLD) cohort, where the drug helped patients reduce liver fat and improve insulin sensitivity
This suggests that the benefits go way beyond appearance
Some preclinical research has explored its potential role in supporting cognitive function, and one study referenced on the ReadyRx website investigated NAD+ supplementation in a mouse model of Alzheimer's disease with impaired DNA repair mechanisms, finding that NAD+ supplementation normalized several disease-related features in that animal model